** Sarepta Therapeutics SRPT.O said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S.-approved gene therapy for Duchenne muscular dystrophy.
DOCTORS COULD BECOME MORE CAUTIOUS
** Jefferies ("buy"; PT: $165) says the therapy Elevidys could perhaps receive a blackbox warning for fatal acute liver-failure as a precautionary measure
** Brokerage adds if the death becomes attributed to SRPT's therapy, adoption could become more skewed towards patients who can walk and a strong trend of use by patients who cannot would reassure the Street about safety fears
** H.C. Wainwright ("sell"; PT: $75) says since the liver failure and death occurred in an older patient who could not walk, doctors could become even more cautious on dosing these patients
** William Blair ("outperform") says the recent infection in patient could have exacerbated the condition, suggesting additional safety screening measures could be implemented in the future to prevent future deaths
** BMO Capital Markets ("outperform"; PT: $200) says while this unfortunately negatively impacts Elevidys' overall safety profile, the benefit/risk profile is acceptable given unmet need in the DMD space
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。